Published in Surgery Litigation and Law Weekly, December 8th, 2006
This trend article about Umea University, Sweden, is an immediate alert from NewsRx to identify developing directions of research.
Study 1: Clear cell and papillary renal cell carcinomas (RCC) bear differential angiogenic profiles.
Researchers in Sweden conducted a study "to examine vascular endothelial growth factor (VEGF), VEGF-receptor-(R)1, and R2 mRNA levels in RCC, a tumor generally refractory to most medical therapy, but for which a potentially useful therapeutic alternative is inhibition of angiogenesis. VEGF, VEGF-R1 and -R2 mRNA levels were analysed using the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Surgery Litigation and Law Weekly